These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20965606)

  • 1. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
    Campbell AM; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking.
    Cheng F; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2010 Sep; 235(9):1093-101. PubMed ID: 20705629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
    Zagon IS; Rahn KA; Bonneau RH; Turel AP; McLaughlin PJ
    Brain Res; 2010 Jan; 1310():154-61. PubMed ID: 19931226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
    Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
    Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
    Zagon IS; Ruth TB; McLaughlin PJ
    Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
    Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
    Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
    Zagon IS; McLaughlin PJ
    Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
    Immonen JA; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
    Zagon IS; Porterfield NK; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer.
    Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
    Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
    BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck.
    McLaughlin PJ; Verderame MF; Hankins JL; Zagon IS
    Int J Mol Med; 2007 Mar; 19(3):421-8. PubMed ID: 17273790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
    Donahue RN; McLaughlin PJ; Zagon IS
    Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
    Zagon IS; McLaughlin PJ
    Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Zagon IS; Donahue R; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.